Investing.com - Truist Securities reiterated a Buy rating and $200 price target on Axsome Therapeutics (NASDAQ:AXSM) on Monday. The biopharmaceutical company, with a market cap of $8.73 billion, has ...

Aashika’s near two decades stint in business and finance journalism has led her to report, write, edit and lead teams covering public investing, private investing and personal investing both in India ...

SBA microloans can be a good choice for small-business owners who may not qualify for more traditional loan options. Many, or all, of the products featured on this page are from our advertising ...

Auto-brightness can be a frustrating feature when you don't want to deal with it. Here's how to ditch it for good. With more than a decade of experience, Nelson covers Apple and Google and writes ...

The Mondraker Summum has been a not-so-guarded secret in the last 6 months, and this World-Cup and USA DH National Champs winning bike has been ridden hard by Ronan Dunne and Ryan Pinkerton in that ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Ryan Eichler holds a B.S.B.A with a concentration in Finance from Boston University. He has ...

Alexandra Twin has 15+ years of experience as an editor and writer, covering financial news for public and private companies. Robert Kelly is managing director of XTS Energy LLC, and has more than ...

MicroAlgo (MLGO) is facing significant challenges with a 1.1% return on capital employed (ROCE), far below the industry average of 9.8%. Despite recent technological advancements and inclusion in the ...